Autoimmune gastritis: problems of diagnosis and therapy
Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 4
Abstract
Chronic gastritis (CG) is one of the most widespread internal diseases, which affects up to 20 % of the adult population. The modern CG paradigm considers disease as a launchpad for the formation of stomach cancer, as well as erosive and ulcerative lesions, including those induced by anti-inflammatory drugs’ intake. The widespread symptoms of gastric dyspepsia often lead to the CG overdiagnosis, while verification of the diagnosis should be based on clinical endoscopic and pathomorphological criteria. In recent years, a large body of scientific data has been presented on the role of different types of microorganisms, including H. Pylori bacteria, of the duodenogastric reflux, medications’ intake in the CG development and progression. However, the autoimmune form of this disease is poorly understood. It is well known that autoimmune gastritis (AIG) is the most important factor in the development of pernicious anemia, and hypochlorhydria leads to iron deficiency anemia. At the same time, the role of AIG in the formation of gastric atrophy and metaplasia is not well understood. A question of gastro-carcinogenic potential of AIG remains open. Diagnosis of AIG requires the determination of not only clinical endoscopic, histopathological parameters, but also a comprehensive analysis of serological data. From the standpoint of modern classifications: Kyoto consensus and the OLGA/OLGIM CG system, it is of interest to correlate between serological and pathological markers in patients with AIG. The treatment of AIG is not specific and does not fundamentally differ from the treatment of other forms of CG. However, given the pathogenetic features of AIG, the development of methods for the correction of immunopathological processes that characterize this disease is promising. AIG treatment is aimed of the infection eradication, restoration of the motor-evacuation function of the gastroduodenal zone, neutralizing the damaging effects of bile acids, but gastroprotection is a strategic direction in the treatment of the disease. In particular, the use of drugs based on bismuth salts promotes restoration of the structural and functional state of the gastric mucosa, inhibits the progression of AIG, as well as promotes regression of atrophy and intestinal metaplasia.
Authors and Affiliations
M. Yu. Zak, S. V. Muzyka, M. O. Klymenko
Inflammatory bowel diseases; 14th Congress of the European Crohn’s and Colitis Organisation (ECCO)
-
The restoration of stomach mucosa in patients with chronic erosive Helicobacter pylori-associated gastritis
Objective — to investigate efficacy of preparation of pro-vitamin B5 and vitamin U in the complex therapy of patients with chronic erosive gastritis, associated with H. pylori, combined with the pancreas excretory insuff...
Modern approaches to the treatment of combed non-alcoholic fatty liver disease and cardiovascular disease
Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and it progresses from simple steatosis to steatohepatitis, fibrosis and cirrhosis. It has been proven that NAFLD is a multisystem disea...
Issues of concern in the diagnosis, treatment and eradication control for the Helicobacter pylori infection at the stage of primary healthcare (based on the results of questioning of primary care physicians)
Objective — based on the results of questioning of primary care physicians, to investigate the status of their awareness regarding the diagnosis, treatment and eradication control for the Helicobacter pylori infection in...
Mechanisms of formation of the gastroesophageal reflux disease and coronary heart disease comorbidity
Objective — to identify possible transnosological mechanisms for the formation of comorbidity of gastroesophageal reflux disease (GERD) and coronary heart disease (CHD). Materials and methods. The study involved patients...